Common Use

Inspra is a selective aldosterone antagonist containing eplerenone, a modern potassium-sparing diuretic prescribed for two critically important cardiovascular indications: the treatment of high blood pressure (hypertension) and the improvement of survival and reduction of hospitalization in patients with heart failure following a myocardial infarction (post-MI treatment). Eplerenone works through a highly targeted mechanism — it selectively blocks aldosterone receptors in the kidneys, heart, blood vessels, and brain, preventing aldosterone from exerting its harmful effects. Aldosterone is a powerful mineralocorticoid hormone produced by the adrenal glands that normally promotes sodium and water retention while increasing potassium excretion; in excess, it contributes to fluid overload, elevated blood pressure, cardiac fibrosis, and progressive cardiovascular damage. By blocking these aldosterone receptors, Inspra helps the body eliminate excess sodium and fluid without depleting essential potassium, effectively reducing blood pressure and significantly decreasing the pathological workload and structural remodeling of the heart. When you buy Inspra online, you access a clinically proven cardiovascular medication backed by landmark clinical trials — including the EPHESUS and EMPHASIS-HF studies — that have demonstrated significant and meaningful reductions in both morbidity and mortality in post-heart attack patients with left ventricular systolic dysfunction and in patients with chronic systolic heart failure. As an Inspra generic equivalent, eplerenone provides identical cardiovascular protective benefits at a more affordable and accessible price point, enabling more patients to benefit from this evidence-based treatment. This aldosterone antagonist has earned its place as an essential component of guideline-directed heart failure treatment protocols recommended by major cardiology societies worldwide, and as a valuable addition to comprehensive hypertension management strategies — particularly for patients with resistant hypertension, metabolic syndrome, or concomitant heart and kidney disease.

Dosage and Direction

Take Inspra by mouth once or twice daily, with or without food, exactly as prescribed by your healthcare provider. For the treatment of high blood pressure, the typical starting dose of eplerenone is 50 mg once daily, which may be increased to the maximum recommended dose of 50 mg twice daily (100 mg total per day) if blood pressure control remains inadequate after a 4-week treatment period. For post-MI heart failure treatment and chronic heart failure with reduced ejection fraction, the starting dose is intentionally conservative at 25 mg once daily, with gradual up-titration to the target dose of 50 mg once daily within 4 weeks, as tolerated and guided by your serum potassium levels and kidney function. Swallow each eplerenone tablet whole with a full glass of water at the same time each day to ensure consistent cardiovascular protection and stable drug levels throughout the dosing interval. Your prescribing doctor will determine the most appropriate dosage based on your specific clinical condition, the severity of your heart failure or hypertension, current kidney function (measured by eGFR or creatinine clearance), and serum potassium levels. Regular blood tests — including serum potassium, sodium, creatinine, and eGFR — are absolutely essential during the dose titration period and throughout long-term treatment. Do not independently adjust your dose, skip doses, or discontinue this aldosterone antagonist without explicit medical guidance, as abrupt changes in therapy may lead to worsening blood pressure control, fluid retention, electrolyte instability, or deterioration of heart failure symptoms.

Precautions

Before you buy eplerenone or initiate Inspra therapy, it is critically important to inform your doctor comprehensively about your medical history, current health status, and all medications you are taking. Pay particular attention to disclosing any history of or current kidney disease or impaired renal function, elevated potassium levels (hyperkalemia) or any history of hyperkalemic episodes, type 2 diabetes mellitus (especially with microalbuminuria or proteinuria), liver impairment or hepatic dysfunction, or concurrent use of any medications known to raise potassium levels. The single most important and potentially life-threatening precaution associated with this potassium-sparing diuretic is the risk of hyperkalemia — dangerously elevated blood potassium levels that can cause fatal cardiac arrhythmias including ventricular fibrillation and cardiac arrest. For this reason, rigorous and regular laboratory monitoring of serum potassium levels and kidney function is absolutely mandatory throughout treatment with Inspra. Blood tests should be performed before initiating treatment (to establish baseline values), within the first week of therapy, at one month, and at regular intervals (typically every 3 months) thereafter — with additional testing performed whenever the dose is changed, if kidney function deteriorates, or if new interacting medications are added. Proactively avoid potassium supplements, potassium-containing salt substitutes (such as "lite salt" or "no salt"), and extreme dietary potassium intake while taking Inspra unless your doctor has specifically directed otherwise after careful assessment. Patients with any degree of impaired kidney function face a substantially greater risk of hyperkalemia and typically require lower starting doses, slower dose titration, and more frequent potassium monitoring. If you develop any signs or symptoms potentially suggestive of hyperkalemia — including unusual muscle weakness, fatigue, slow or irregular heartbeat, palpitations, tingling sensations in the extremities, nausea, or a feeling of chest heaviness — seek prompt medical attention for urgent potassium level assessment. Be sure to inform all healthcare providers involved in your care — including surgeons, dentists, anesthesiologists, and emergency physicians — that you are taking this cardiovascular medication, as this information is essential for safe perioperative and emergency management.

Contraindications

Do not use Inspra if your serum potassium level is greater than 5.0 mEq/L at the time of treatment initiation, as starting eplerenone with already elevated potassium creates an unacceptable risk of severe, life-threatening hyperkalemia. This aldosterone antagonist is contraindicated in patients with severe kidney impairment (creatinine clearance of 30 mL/min or less, or eGFR below 30 mL/min/1.73m²), as dramatically reduced renal potassium excretion compounds the hyperkalemia risk to a dangerous degree. Concurrent use with strong CYP3A4 inhibitors — including but not limited to ketoconazole, itraconazole, nefazodone, clarithromycin, ritonavir, and nelfinavir — is strictly contraindicated, as these medications dramatically increase eplerenone blood levels, magnifying both therapeutic and toxic effects. Inspra must not be used by patients with a known allergy or hypersensitivity to eplerenone or any excipient present in the tablet formulation. For the hypertension indication specifically, eplerenone should not be used concurrently with other potassium-sparing diuretics (such as spironolactone, triamterene, or amiloride) or with potassium supplements, as the additive potassium-retaining effects create a high risk of severe hyperkalemia. Patients with type 2 diabetes and microalbuminuria who are already receiving treatment with ACE inhibitors or ARBs should not receive eplerenone due to the compounded and clinically documented risk of hyperkalemia in this specific patient population. Inspra generic formulations carry identical contraindications to the branded product. Additionally, severe hepatic impairment (Child-Pugh Class C) represents a contraindication, as eplerenone metabolism may be significantly impaired, leading to unpredictable drug accumulation and increased toxicity risk.

Possible Side Effect

Common side effects of eplerenone include dizziness (especially during the initial treatment period or after dose increases), diarrhea, fatigue, mild nausea, abdominal discomfort, and cough. These effects are generally mild, dose-related, and tend to diminish as your body adjusts to the medication over the first few weeks of treatment. The most clinically significant and potentially dangerous adverse effect is hyperkalemia (elevated blood potassium), which occurs with notably higher frequency in patients with pre-existing impaired kidney function, diabetes mellitus, advanced age, or those taking concurrent medications that independently raise potassium levels. The warning signs and symptoms of hyperkalemia include progressive muscle weakness and fatigue, numbness or tingling sensations (particularly in the extremities), slow or irregular heartbeat, palpitations, chest discomfort, nausea, and — in severe, life-threatening cases — complete cardiac arrest. Other clinically notable side effects include hyponatremia (low blood sodium, potentially causing confusion, headache, and lethargy), mild and usually transient elevations in serum creatinine reflecting reduced kidney filtration pressure, elevated triglyceride levels, and flu-like symptoms including headache and upper respiratory tract symptoms. An important advantage of eplerenone compared to the older, related aldosterone antagonist spironolactone is the significantly lower incidence of anti-androgenic side effects — gynecomastia (breast enlargement or tenderness in men), sexual dysfunction, and menstrual irregularities are substantially less frequent with eplerenone due to its greater selectivity for the mineralocorticoid receptor. Serious side effects that demand immediate medical attention include symptoms of severe or symptomatic hyperkalemia, signs of allergic reaction (skin rash, itching, facial or throat swelling, difficulty breathing), and significant or sudden changes in urine output suggesting acute kidney injury. Contact your healthcare provider promptly if you experience any unusual, persistent, or worsening cardiovascular symptoms during treatment.

Drug Interaction

Inspra has several critically important drug interactions that must be carefully recognized and managed to ensure treatment safety. Concurrent use with other potassium-sparing diuretics (spironolactone, amiloride, triamterene), potassium supplements in any form, or potassium-containing salt substitutes significantly and additively increases the risk of life-threatening hyperkalemia and is generally contraindicated or requires exceptionally close monitoring. ACE inhibitors (enalapril, lisinopril, ramipril) and ARBs (losartan, valsartan, candesartan) — which are frequently co-prescribed in heart failure protocols — also independently raise potassium levels and must be used with careful, ongoing monitoring of serum potassium and renal function when combined with this aldosterone antagonist. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin) are strictly contraindicated with eplerenone as they can increase drug exposure by 2 to 5 fold, dramatically raising the risk of severe hyperkalemia and other adverse effects. Moderate CYP3A4 inhibitors (erythromycin, verapamil, diltiazem, fluconazole, amprenavir) require mandatory eplerenone dose reduction to no more than 25 mg once daily when co-administered. NSAIDs (ibuprofen, naproxen, diclofenac, celecoxib) may reduce the antihypertensive and natriuretic effectiveness of Inspra, worsen kidney function, and independently promote potassium retention — use this combination with caution and enhanced renal monitoring. Lithium toxicity risk increases meaningfully with concurrent eplerenone use, as reduced renal lithium clearance may lead to dangerous lithium accumulation. This potassium-sparing diuretic may also enhance the blood pressure-lowering effects of other antihypertensive agents, increasing the risk of symptomatic hypotension — dose adjustments may be necessary when multiple blood pressure medications are used together. Provide your doctor and pharmacist with a complete and updated list of all prescription medications, over-the-counter drugs, vitamins, dietary supplements, and herbal products you are taking before starting or modifying your cardiovascular treatment with Inspra.

Missed Dose

If you miss a dose of Inspra, take it as soon as you remember on the same day, unless it is already close to the time for your next scheduled dose. In that case, skip the missed dose entirely and continue with your regular dosing schedule — do not take two doses at once or within a short timeframe to compensate for the forgotten dose, as this could cause a sudden increase in potassium-sparing effect and elevate your risk of hyperkalemia. Consistent, uninterrupted daily use of this aldosterone antagonist is critically important for maintaining effective and stable blood pressure control, sustaining the cardioprotective benefits in heart failure management, and preventing fluid reaccumulation and neurohormonal reactivation. If you regularly forget to take your doses, consider practical adherence strategies such as using a daily pill organizer, setting recurring phone reminders, linking your medication schedule with another consistent daily routine (such as breakfast or brushing your teeth), or asking a family member to help remind you. Contact your healthcare provider if you miss several consecutive doses of this cardiovascular medication, as your blood pressure, potassium levels, and heart failure status may need reassessment before safely resuming treatment.

Overdose

In case of suspected or confirmed Inspra overdose, seek immediate emergency medical attention without delay. The primary and most dangerous concern is severe hyperkalemia — dangerously elevated blood potassium levels that can trigger life-threatening cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation, complete heart block, and ultimately cardiac arrest. Overdose may also produce marked and sustained hypotension (dangerously low blood pressure), causing severe dizziness, mental confusion, loss of consciousness, cardiovascular collapse, and end-organ damage. Clinical signs and symptoms of hyperkalemia in the overdose setting include extreme and progressive muscle weakness, ascending paralysis, slow or grossly irregular heartbeat, prominent tingling sensations, nausea, and characteristic ECG changes (peaked T waves, widened QRS complex, loss of P waves). Emergency treatment is focused primarily on rapidly correcting potassium levels through intravenous calcium gluconate (for immediate cardiac membrane stabilization), insulin with glucose (to drive potassium into cells), inhaled beta-agonists, sodium bicarbonate (for concurrent acidosis), and potentially urgent hemodialysis in severe or refractory cases. It is important to note that eplerenone itself is not significantly removed by standard hemodialysis due to its extensive plasma protein binding, but dialysis remains effective for directly correcting the life-threatening hyperkalemia. Continuous cardiac monitoring, frequent electrolyte reassessment, and hemodynamic support are essential throughout the treatment and recovery period.

Storage

Store Inspra at controlled room temperature between 20°C and 25°C (68°F to 77°F), with brief excursions permitted between 15°C and 30°C (59°F to 86°F). Protect the medication from moisture, direct light exposure, and excessive heat, as these environmental conditions can compromise the chemical stability and therapeutic potency of eplerenone. Keep the tablets in their original container with the cap or closure tightly secured. Do not store in the bathroom, kitchen, or other locations with high humidity levels. Keep Inspra and all cardiovascular medications well out of reach of children and household pets. Do not use past the expiration date clearly printed on the packaging, as expired medication may have reduced efficacy and unpredictable safety characteristics. Dispose of expired or unused eplerenone tablets properly and safely — consult your pharmacist about recommended medication disposal programs available in your community or follow applicable environmental guidelines for prescription medication disposal.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.